DELTA PLUS

Covaxin third dose demonstrates long-term safety with no serious adverse events, study

Reactogenicity after vaccine and placebo was minimal and comparable,and no serious adverse events were reported, the study indicates.

More in DELTA PLUS

Chandigarh reports first case of Delta Plus COVID-19 variant

As per a statement from the Chandigarh administration, 50 random samples of Chandigarh residents from May and June were sent to the National Centre for Disease Control (NCDC) lab on June 6 for Whole Genome Sequencing (WGS).
Delta may outfox even fully vaccinated: Doctors

Covid could turn more severe for those affected during the third wave of the pandemic, including for around 5% to 10% of third-wave patients who would be fully vaccinated by then, because of mutations like Delta and Delta Plus, experts have warned.
NIV to test if Covaxin can fight off Delta Plus variant of coronavirus

The recently discovered Delta Plus variant of SARS-CoV-2 will be isolated and grown at the ICMR-National Institute of Virology to test if it can be neutralised by Bharat Biotech's Covaxin.
Delta+ variant not yet classified as 'Variant of Concern': Niti Aayog's V.K. Paul

As 'Delta Plus' is not yet classified as a VOC, Paul said, the way forward is to watch the potential presence of 'Delta Plus' in the country and take the appropriate public health response.